The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of Massachusetts

Thomas Jefferson University

Centers for Disease Control and Prevention

Charles E Rupprecht

Xianfu Wu

Gregory Babcock

William D Thomas, Jr

Robert Barry Mandell

Donna Ambrosino

Bernhard Dietzschold

Susan Sloan

Hilary Koprowski

Matthias Johannes Schnell

D Craig Hooper

Ivan V Kuzmin

Robert Mandell

William D Thomas

Susan Schonhoff

Gregory J Babcock

Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologousglycoproteins. The disclosed recombinant rabies viruses can be used as pan-vaccines to provide protection againstthat cause rabies.

Pan-lyssavirus vaccines against rabies

Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus.

Rabies virus vector systems and compositions and methods thereof

Described herein are recombinant rabies viruses comprising a heterologous nucleic acid sequence encoding an immunocontraceptive protein, such as gonadotropin-releasing hormone (GnRH) or zona pellucida 3 (ZP3). The recombinant rabies viruses disclosed herein are recovered by reverse genetics, replicate efficiently, elicit rabies virus neutralizing antibodies and immunocontraceptive peptide-specific antibodies in vaccinated animals, and protect vaccinated animals against wild-type rabies virus challenge. Further provided is a method of immunizing a non-human animal against rabies virus infection and simultaneously inhibiting fertility of the animal, comprising administering an immunogenic composition comprising one or more of the recombinant rabies viruses described herein.

Rabies virus-based recombinant immunocontraceptive compositions and methods of use

Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein.

Human antibodies against rabies and uses thereof

Live, attenuated recombinant rabies virus vaccines are generated using reverse genetics to combine the antigenic determinants that render the rabies virus non-pathogenic with the determinants that are responsible for the elicitation of an effective anti-rabies immune response. These vaccines do not affect the antigenic, and therefore the immunogenic, properties of the virus. The present invention further relates to recombinant rabies virus vaccines that express a pro-apoptotic protein, such as cytochrome c, to increase the capacity to induce apoptosis, thereby enhancing the protective immunity against rabies. This new generation of live rabies virus vaccines represents a safe and effective approach to the eradication of rabies in wildlife, and subsequently humans and livestock.

Genetically engineered rabies recombinant vaccine for immunization of stray dogs and wildlife

Pharmaceutical compositions that comprise a pharmaceutically acceptable carrier or diluent and a antibodies that each comprise at least a portion of the variable region from MAb 1112-1 are disclosed. Methods of treating individuals suspected of exposure to rabies are disclosed.

Methods for treating post-exposure rabies and anti-rabies compositions

Growing community of inventors

Lawrenceville, GA, United States of America

Charles E Rupprecht